Ona Therapeutics
ona-therapeutics.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$86.6M
1 round on record
Latest round
$86.6M
Series B · Jun 2026 · 3 mo ago
Team
51-200
employees, estimated range
Backers
4
Asabys Partners, Fund+
The money's age
Fresh money
3 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2019
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Jun 2026 | $86.6M | — | streetinsider.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Asabys Partners 
Fund+ 
Mérieux Equity Partners 
Ysios Capital Similar startupsby what they do, their industry and backers
Building tomorrow's antibody-drug conjugates (ADCs). Araris Biotech AG, a spin-off company from the Paul Scherrer Institute (PSI) and ETH…
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs) to address the hallmarks of cancer lethality.
THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse…
Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need…
Novel ADC Payloads for Cancer Hexagon Bio is developing novel payload mechanisms for antibody-drug conjugates (ADCs) to overcome resistance…
FROM CELLS TO ORGANELLES• ORGANELLES•. First-in-Class Isolated Organelles for Drug Discovery.
News
Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer
More than half of the patients planned for the clinical study have already been enrolled, with the trial progressing rapidly through dose escalati...
Read more
Report
WuXi XDC Grants Ona Therapeutics Global Rights To WuXiTecan-2 Payload-Linker Platform
WuXi XDC Cayman Inc. (2268.HK), a CRDMO specializing in antibody-drug conjugates and bioconjugates, has entered into an out-licensing agreement granting Ona Therapeutics an exclusive worldwide license to its proprietary WuXiTecan-2 payload-linker technolo
Read more
Report
WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development
WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced an out-licensing colla
Read more
Report
China's WuXi XDC out-licenses Payload-Linker Technology Platform to Ona Therapeutics for ADC research
Read more
Report
Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development
Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investorsProceeds to support clinical development of le
Read more
Report
Pro access
Upgrade to see all 9 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Financials
Total raised
$86.6M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2026 | $86.6M | Details |